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Background: Factors related to the natural transmission of Ebola virus (EBOV) to humans are still not well defined.
Results of previous sero-prevalence studies suggest that circulation of EBOV in human population is common in
sub-Saharan Africa. The Efé pygmies living in Democratic Republic of the Congo are known to be exposed
to potential risk factors of EBOV infection such as bush meat hunting, entry into caves, and contact with
bats. We studied the pygmy population of Watsa region to determine seroprevalence to EBOV infection and
possible risks factors.
Method: Volunteer participants (N = 300) aged 10 years or above were interviewed about behavior that may
constitute risk factors for transmission of EBOV, including exposures to rats, bats, monkeys and entry into
caves. Samples of venous blood were collected and tested for IgG antibody against EBOV by enzyme-linked
immunosorbent assay (ELISA). The χ2-test and Fisher’s exact test were used for the comparison of proportions
and the Student’s t-test to compare means. The association between age group and anti-EBOV IgG prevalence was
analysed by a nonparametric test for trend.
Results: The prevalence of anti-EBOV IgG was 18.7 % overall and increased significantly with age (p = 0.023). No
association was observed with exposure to risk factors (contacts with rats, bats, monkeys, or entry into caves).
Conclusions: The seroprevalence of IgG antibody to EBOV in pygmies in Watsa region is among the highest ever
reported, but it remains unclear which exposures might lead to this high infection rate calling for further ecological
and behavioural studies.
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The Ebolavirus genus, which is in the Filoviridae family,
comprises five distinct virus species: Zaire ebolavirus
(EBOV), Sudan ebolavirus (SUDV), Tai Forest ebolavirus
(TAFV), Reston ebolavirus (RESTV), and Bundibugyo
ebolavirus (BDBV) [1]. EBOV, SUDV, and BDBV have* Correspondence: sabuemulo@yahoo.fr
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to 90 % depending on species [2].
There is currently no specific treatment or vaccine
against EBOV approved for human use. Human-to-
human transmission of the virus is controlled by the im-
plementation of strict public health procedures, including
isolation of probable or confirmed cases. However, inter-
ventions that aim to prevent the primary introduction of
EBOV into human populations are difficult to implement
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unknown.
Until recently, EVD outbreak was considered as an
emerging zoonotic viral disease that occurred mainly in
rural areas of Central Africa. But in December 2013, an
Ebola outbreak has emerged in West Africa which was
unprecedented in magnitude and spread [3]. Historically,
outbreaks of EVD have occurred in sub-Saharan Africa
including in Sudan, Uganda, Gabon, Côte d’Ivoire,
Democratic Republic of the Congo (DRC), and the Re-
public of the Congo. The majority of human outbreaks
have been associated with the manipulation of carcasses
of infected great apes or other wildlife in Gabon and
Republic of the Congo [4]. In other settings where non-
human primates (NHP) or other wildlife were not identi-
fied as the cause of outbreaks (e.g., in DRC, Uganda, and
Sudan), epidemiological investigations based on informa-
tion available from index cases have suggested that bats
might be a source of EVD outbreak [5, 6]. This hypoth-
esis has been supported by the discovery of EBOV viral
gene sequences from fruit bat species, and others bats
have been found to be seropositive for EBOV antigens
[7]. Fruit bats were also suggested as possible original
source of infection based on the ecological investigation
of the current EVD outbreak in Western African coun-
tries [8]. However, it remains unclear how bats or other
carriers actually transmit the virus to humans, NHPs, or
other non-identified hosts, and the parameters that lead
to the occurrence of outbreaks remain to be determined.
Several epidemiological studies have been carried out
to determine the prevalence of past EBOV infections
and associated risk factors in human populations in
countries where EVD outbreaks have occurred (e.g.,
DRC and Gabon) [9–13] and in countries without a his-
tory of epidemics (e.g., Cameroon, Central Africa and
Liberia) [14–19]. Together, these studies have demon-
strated that, although EVD outbreaks are sporadic, ex-
posure to EBOV or ebola-like virus is not a rare event in
human populations in sub-Saharan Africa and that sero-
prelavence is higher in the rainforest ecosystem and in
hunter populations.
Pygmies are hunter-gatherer populations living in
tropical rainforests in Africa and are known for their no-
madic life style that potentially exposes them to EBOV
[20]. Ebola seroprevalence studies have been conducted
in pygmy populations living in Central African countries
including Gabon, Cameroon, and Central African
Republic [10, 14, 15]. In DRC, where at least six docu-
mented outbreaks of EVD have occurred in the last two
decades, several pygmy groups live in the equatorial
rainforests, but there are no published data regarding
their exposures to EBOV. In 2002, a Marburg haemor-
rhagic fever (MHF) seroprevalence survey was con-
ducted in the Efé pygmy population living in the Watsaregion in north-eastern DRC, where an MHF outbreak
occurred between 1998 and 2001 [21]. The main victims
of this MHF outbreak were gold miners from the
Gorumbwa mine in Durba village and their family mem-
bers [22]. There was zero prevalence of IgG anti-
Marburg antibody in 300 pygmies [21], even though they
were reported to be more exposed to risk factors (e.g.,
hunting and butchering bush meat, entry into caves,
and contacts with bats) associated with filovirus infec-
tion [7, 23–25] compared to the general, non-pygmy
population.
To explore whether the Efé pygmy lifestyle in the
Watsa region is related to exposure to EBOV, we investi-
gated previously collected serum samples for evidence of
past EBOV infection and tested associations with poten-
tial risk factors.
Methods
The area, study population, interviews, and blood collec-
tions are described elsewhere [21]. In brief, the Watsa
region in north-eastern DRC had approximately 180,000
inhabitants including 4,000 pygmies living mainly in the
southern part of the region. The study participants came
from 39 different settlements and voluntarily reported to
study sites for interview. During a three days survey in
August 2002, after obtaining informed verbal consent,
participants were asked about their subsistence activities
and contact with wild animals as potential risk factors of
primary filovirus transmission. Exposures to persons
presumably sick with haemorrhagic fever (define as se-
vere illness with high fever and bleeding from the
nose, mouth, and/or anus) in the hospital and at
home, receiving invasive medical or traditional treat-
ment were asked as potential risk factors of secondary
filovirus transmission.
We collected a blood sample from each volunteer and
stored sera were tested for IgG antibodies to EBOV anti-
gen by enzyme-linked immunosorbent assay (ELISA) at
the National Institute for Communicable Diseases,
Johannesburg as previously described [26]. Briefly,
ELISA plates were coated with EBOV antigens diluted
1:1000 in PBS, overnight at +4 °C. Uninfected Vero cell
culture antigens were coated in the same conditions on
ELISA plates as controls. Diluted sera 1:400 in 5 % non-
fat milk in PBS-Tween 20 (0.1 %) were incubated in the
wells overnight at +4 °C. Peroxidase-labelled antibody to
human IgG was added to wells and the TMB detector
system was used to detect binding. We computed the
corrected optical density (OD) as the optical density of
the EBOV-coated well subtracted by the OD of the cor-
responding control well. Corrected ELISA optical dens-
ity values were expressed as percent positivity (PP) of a
human serum sample confirmed positive for EBOV and
used as an internal control. Cut-off value for recording
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at 2 × (mean +3 standard deviations (SD)) PP values de-
termined for 60 serum samples from South African con-
trols subjects who were almost certain to be
seronegative.
The interview data were recorded in a database using
EpiInfo 6.04 (Centers of Disease Control and Prevention,
Atlanta, Georgia, USA), and analysed with STATA 12
(College Station, Texas, USA). When comparing charac-
teristics between seropositive and seronegative individ-
uals the χ2-test and Fisher’s exact test were used to
compare proportions and the Student t-test was used to
compare means. We computed SD for means and confi-
dence intervals (CI) of proportions using the exact
method. Odds Ratios (OR) and exact 95 % confidence
intervals (CI) were used to access the association be-
tween risk factors and EBOV IgG seroprevalence. The
association between age group and anti-EBOV IgG
prevalence was analysed by a nonparametric Cuzick’s
test for trend [27].
The representative of the Ministry of Health in the
Watsa region and the ethics committee of the Institute
of Tropical Medicine in Antwerp approved the study
protocol.Results
As previously published, a total of 300 pygmies were en-
rolled into the study and provided blood samples [21]. The
proportion of male and female individuals was comparable.
EBOV IgG antibodies were found in 56 of the 300 partici-
pants, resulting in an overall prevalence of anti-EBOV IgG
in the pygmy population of 18.7 % (95 % CI 14.4–23.5 %):
20 % (95 % CI 13.9–27.3 %) in males and 17 % (95 % CIFig. 1 Age distribution of individuals with IgG EBOV antibodies in the Wats11.7–24.4 %) in females. The difference between men and
women was not statistically significant in any age group
(χ2-test p = 0.35).
The mean age of the study participants was 32 years
(±SD 14.6). Antibody-positive participants were signifi-
cantly older than antibody-negative participants (35.9 ±
14.7 vs. 31.3 ± 14.5; Student t-test p = 0.03). EBOV
antibody-positive participants were seen in all age
groups, the youngest IgG EBOV-positive participant be-
ing 12 and the oldest 65 years old. A significant
(Cuzick’s test p = 0.023) linear increase in EBOV IgG
prevalence was noted with increasing age group (Fig. 1).
There was no statistically significant difference in
EBOV seroprevalence between groups exposed or unex-
posed to potential risk factors of primary filovirus trans-
mission (hunting, entering caves, and contact with wild
animals) or of secondary transmission in households or
hospitals (Table 1).
The IgG EBOV prevalence was higher in study partici-
pants who had experienced a febrile haemorrhagic syn-
drome at least once in their life than those who had not,
but the difference was not statistically significant (22 %
vs. 16 %; χ2-test p = 0.18).
Discussion
Here, we examined the seroprevalence of EBOV in a
pygmy population in the Watsa area of DRC to establish
whether their previously reported increased exposure to
risk factors than the general population was associated
with filovirus infection.
There was a very high EBOV antibody prevalence
(18.7 %) in this study population, consistent with previ-
ous studies of pygmy populations in Cameroon (14.5 %)
[15], Central African Republic (7.0 %), [14] and Gabona area, DRC (p = 0.023)
Table 1 Antibodies to EBOV and potential risk factors for Ebola virus disease fever in pygmies residing in the Watsa Region, DRC
Potential risk factors: N exposed (% exposed) Exposed
# IgG pos. (%)
Non exposed
# IgG pos. (%)
χ2-test p OR (95 % CI)
Risk factors for primary transmission
Subsistence activities
Hunting: 180 (60) 37 (20.6) 19 (15.8) 0.3 1.38 (0.72, 2.68)
Entering caves: 295 (98) 55 (18.6) 1 (20.0) 0.66b 1.19 (0.64, 2.23)
Contacts with wild animals
Rodents
Touched: 216 (72) 42 (19.4) 14 (6.7) 0.58 1.21 (0.60, 2.54)
eatena : 127 (42) 20 (15.8) 36 (20.8) 0.27 0.71 (0.37–1.35)
bitten by : 91 (30) 15 (16.5) 41(19.6) 0.52 0.81 (0 .39, 1.60)
any contact : 238 (79) 45 (18.9) 11 (17.7) 0.83 1.08 (0.53, 2.33)
Bats
Touched : 224 (75) 43 (19.6) 13 (17.1) 0.69 1.15 (0.56, 2.49)
eatena : 160 (53) 33 (20.6) 23 (16.4) 0.35 1.03 (0 .21, 10.10)
bitten by : 57 (19) 9 (16.1) 47 (19.3) 0.53 0.78 (0.32, 1.76)
any contact : 233 (78) 45 (19.3) 11 (16.4) 0.59 1.21 (0.60, 2.61)
Monkeys, apes
Touched : 273 (91) 52 (19.0) 4 (14.8) 0.80b 1.35 (0 .44, 5.61)
eatena : 289 (96) 54 (18.7) 2 (18.2) 1.00b 1.03 (0 .21, 10.10)
bitten by : 16 (5) 3 (18.8) 53 (18.7) 1.00b 1.01 (0 .18, 3.84)
any contact : 294 (98) 56 (19.0) 0 (0.0) 0.28b
Wild animals: any contact : 296 (97) 56 (18.9) 0 (0.0) 0.43b
Risk factors for secondary transmission
Contact with someone suffering from HF§
had someone with HF in the household : 66 (22) 7 (10.6) 49 (20.9) 0.06 0.45 (0.16, 1.07)
been in the same room with someone with HF : 47 (16) 8 (17.0) 48 (18.9) 0.75 0.88 (0.33, 2.06)
worked with someone with HF : 61 (20) 9 (14.7) 47 (19.7) 0.38 0.71 (0.29, 1.59)
participated in funeral of someone with HF : 65 (22) 12 (18.5) 44 (18.7) 0.96 0.98 (0.44, 2.07)
touched someone with HF : 57 (19) 11 (19.3) 45 (18.5) 0.89 1.05 (0.45, 2.27)
touched blood, urine, faeces of someone with HF : 34 (11) 8 (23.5) 48 (18.0) 0.44 1.40 (0.51, 3.42)
touched remains of someone with HF : 44 (15) 12 (27.3) 44 (17.2) 0.11 1.81 (0.78, 3.94)
any contact : 102 (34) 16 (15.7) 40 (20.2) 0.34 0.74 (0.38, 1.38)
any direct contact (touched) : 79 (26) 16 (20.3) 40 (18.1) 0.67 1.15 (0.59, 2.18)
Invasive medical treatment
ever received injection : 263 (88) 51 (19.4) 5 (13.5) 0.39 1.54 (0.56, 5.31)
ever received surgical or obstetric care : 124 (41) 27 (21.8) 29 (16.5) 0.24 1.41 (0 .75, 2.63)
any invasive medical treatment ever : 278 (93) 54 (19.4) 2 (9.1) 0.18b 2.41 (0.63, 15.66)
Traditional treatment
ever had scarification : 294 (98) 54 (18.4) 2 (33.3) 0.4 0 .45 (0.06, 5.11)
aBush meat often is smoked, grilled or cooked; exposure to viable virus may therefore be more likely to happen during preparation of such meat for consumption
than during consumption itself
bFisher’s Exact Test
§: HF (haemorrhagic fever): severe illness with high fever and bleeding from the nose, mouth, and/or anus
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test in the studies in Central African Republic and
Gabon, whereas an immunofluorescence antibody (IFA)
test was used in the Cameroon study. The ELISA test we
used had Zaire ebolavirus species as source of antigen.
This assay is more specific and sensitive for the detec-
tion of past infection than the standard IFA test [28, 29]
and has the potential to detect cross-species ebolavirus
antibodies [30]. Therefore, the pygmy seroprevalence re-
flects a relatively high level of exposure to EBOV or to
other cross-reactive ebolavirus species in the study area.
Since the EBOV species is known to be very pathogenic
with a high case fatality proportion, this seroprevalence
might underestimate the level of exposure to EBOV by
assessing only the survivors. Alternately, our study
population may have been exposed to other known or
unknown ebolavirus species of lower pathogenicity,
which may cause cross-reaction with the assay and con-
tribute to the high seroprevalence [30, 31].
This study was a retrospective survey using stored
pygmy sera, and comparison sera from the general
sedentary population in the Watsa area were unavail-
able. However, two EBOV seroprevalence studies using
the same ELISA assay conducted in the sedentary
population in Kikwit city (the epicenter of a major
EVD outbreak in 1995) and neighbouring villages,
DRC, reported a prevalence of 2.2 % and 9.3 %, re-
spectively [9]. The fact that the Efé pygmy population
in Watsa tended to have a higher EBOV prevalence
than non-pygmy inhabitants of Kikwit city and sur-
rounding villages is in line with studies in Cameroon,
Gabon, and Centre African Republic [10, 14, 15].
We found that EBOV IgG seroprevalence in Watsa
pygmies increases significantly with age and is max-
imal in the 60 years and older age group. Other EBOV
seroprevalence studies have shown that seroprevalence
was highest in individuals aged between 20 and
40 years [9, 10, 14, 15]. The different distributions of
seroprevalence by age may be due to differences in
lifestyle between study populations. Non-pygmies may
be more likely to enter deep into the rain forest for
economic survival activities and to be exposed to a
variety of putative EBOV animal hosts when they are
in the economically most active 20–40 year age group.
The Efé pygmies, however, who live in the rain forest
all their life, may accumulate exposure to putative
EBOV animal hosts throughout life, which is reflected
by a linear seroprevalence increase with age. The fact
that EBOV seroprevalence in pygmies in RCA [14] and
Gabon [10] was highest in the 20-40 year old age
group may reflect the trend that Aka and Baka pyg-
mies in those areas have started to abandon their trad-
itional semi-nomadic lifestyle in favour of the
sedentary farmer’s life [32].Here, there was no association between risk factors for
primary or secondary transmission of filoviruses and
EBOV antibody status. Some of the non-significant dif-
ferences observed may be real, but our study may have
been insufficiently powered to detect them. For instance,
categorisation of the level of exposure for participants in
contact with someone suffering from haemorrhagic fever
might reveal significant differences. Furthermore, our
study was limited by the fact that study participants
were not selected randomly but were self-recruited, al-
though we have no reason to believe that this resulted in
selection bias.
Conclusion
Pygmy populations are known to be particularly at risk of
filovirus exposure compared to sedentary populations.
Here, pygmies in the Watsa region of DRC were at high
risk and had one of the highest reported seroprevalence of
EBOV IgG antibodies using a well-established ELISA assay.
Since we could not identify risk factors that could explain
this high prevalence, further ecological and behavioural
studies might be necessary to better understand determi-
nants of EBOV exposure in this population.
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